Food and Drug Administration v Alliance for Hippocratic Medicine —A Cautious Win for Reproductive Health Care and FDA Authority
JAMA · 2024
DOI: 10.1001/jama.2024.13161 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, 2024. Verfasst von Michele B Goodwin und 2 weiteren Autor:innen. Beteiligte Einrichtung: O'Neill Institute for National and Global Health Law, Georgetown University Law Center, Washington, DC. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Reproductive Health Services, Abortion, Induced, Health Services Accessibility. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
This Viewpoint discusses the recent US Supreme Court ruling allowing mifepristone—a drug used in medication abortion—to be widely available in the US, summarizes the history of challenges to the availability of mifepristone, and highlights reasons for concerns that remain after the Court’s current ruling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- O'Neill Institute for National and Global Health Law, Georgetown University Law Center, Washington, DC.
- Georgia State University College of Law, Atlanta.
Zitieren
APA
Goodwin, M. B., Whelan, A. M., & Gostin, L. O. (2024). Food and Drug Administration v Alliance for Hippocratic Medicine —A Cautious Win for Reproductive Health Care and FDA Authority. JAMA. https://doi.org/10.1001/jama.2024.13161
Vancouver
Goodwin MB, Whelan AM, Gostin LO. Food and Drug Administration v Alliance for Hippocratic Medicine —A Cautious Win for Reproductive Health Care and FDA Authority. JAMA. 2024. doi:10.1001/jama.2024.13161
BibTeX
@article{Goodwin2024,
author = {Goodwin, Michele B and Whelan, Allison M and Gostin, Lawrence O},
title = {Food and Drug Administration v Alliance for Hippocratic Medicine —A Cautious Win for Reproductive Health Care and FDA Authority},
journal = {JAMA},
year = {2024},
doi = {10.1001/jama.2024.13161}
}
EUVIMED